Kurzfassung

A multicenter, double-blind, randomized, placebo-controlled, phase III study of Idasanutlin, an MDM2 antagonist, with Cytarabine versus Cytarabine plus placebo in patients with relapsed or refractory Acute Myeloid Leukemia